Given that our cohort consisted of early‐stage lung cancer, we aimed to investigate the comparability of EGFR mutation frequency as a reference point by comparing the WES data of nonsmokers in our current cohort (early stage, MIA/IA) with the CHOICE cohort (late‐stage). This evidence concerns the gene EGFR and lung carcinoma.